Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.

about

Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight.Emerging therapies in advanced hepatocellular carcinoma

P2860

Q52345488-0A264E5E-7DFC-4118-92DB-D57FEDD6AE28 Q58802297-3D255C78-BE88-4C85-8380-C15D12AE33A9

P2860

Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.

Item

http://www.wikidata.org/entity/Q38873430

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.

@en

type

Item

label

Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.

@en

prefLabel

Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.

@en

P1476

Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.

@en

P2093

Jiabei Wang

http://www.w3.org/2001/XMLSchema#string

Keyu Li

http://www.w3.org/2001/XMLSchema#string

Lianxin Liu

http://www.w3.org/2001/XMLSchema#string

Yaliang Lan

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Tumor markers for hepatocellular carcinoma (Review)

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Cancer regression in patients after transfer of genetically engineered lymphocytes

Potentiality of immunotherapy against hepatocellular carcinoma

Sorafenib in advanced hepatocellular carcinoma

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Reversal of tumor immune inhibition using a chimeric cytokine receptor.

P304

1010428317692229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1010428317692229

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28347250

http://www.w3.org/2001/XMLSchema#string

Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.

about

P2860

P2860

Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698